✦ The essentials in 30 seconds
Researchers at UCLouvain have identified a gene — TIE1 — whose mutations cause late-onset lymphedema. Out of 755 affected patients, 3 carried mutations in this gene. It's a key advance for the thousands of people whose underlying cause remains unknown.
What is lymphedema?
You're probably familiar with blood vessels, which carry blood. But your body has a second network of vessels: the lymphatic vessels. Their role? To drain fluid, waste, and immune cells from tissues.
When this network malfunctions, fluid accumulates — often in the arms or legs. That's lymphedema: chronic swelling, uncomfortable, sometimes painful. There's no definitive cure today.
Lymphedema can occur at any age. But when it appears without obvious cause — no surgery, no cancer — it's called primary lymphedema. And in that case, doctors typically look for a genetic cause.
The problem: 70% of cases still have no explanation
About thirty genes are currently known which, when defective, can cause primary lymphedema. But here's the catch: even after testing all of them, we only find an explanation for roughly 30% of patients.
The remaining 70% have unexplained lymphedema. For these patients and their families, having no answer makes the disease even harder to live with.
What the Vikkula team discovered
Prof. Miikka Vikkula and his team at the de Duve Institute (UCLouvain) screened the genomes of 755 patients with primary lymphedema. Their goal: find new causative genes.
Of these patients, 3 carried mutations in the TIE1 gene — a gene known to biologists since 1992, but whose precise role had remained mysterious.
What the team showed: these mutations break the TIE1 protein. And when TIE1 no longer works correctly, lymphatic vessels develop poorly or function deficiently. The result: lymphedema.
🔍 Key takeaways
- →Primary lymphedema affects thousands of people across Europe
- →70% of cases still have no genetic explanation
- →TIE1 is a newly identified causative gene — discovered at UCLouvain
- →This discovery opens the way to better diagnosis and future treatments
✦ Bottom line
This discovery isn't a cure yet — but it changes something essential.
For patients with unexplained lymphedema, having a name — a precise mutation in a precise gene — already means a lot. It turns an invisible disease into something real, measurable. And it opens the door to targeted treatments that research can't yet design without knowing where to look. The UCLouvain team hasn't found a definitive answer. They've found the right question — and that's often where everything begins.
✦ Free newsletter
Want the next article
straight to your inbox?
Free · Zero spam · Next article drops this week.
✦ Intermediate summary
By sequencing the exomes of 755 patients with primary lymphedema, the Vikkula team (UCLouvain) identified 3 pathogenic TIE1 variants — an orphan receptor tyrosine kinase. These mutations induce a loss of function of TIE1 and disrupt the ANGPT2/TIE1 pathway, which is crucial for the development and maintenance of lymphatic vessels.
The lymphatic system and its molecular actors
Lymphatic vessel development is orchestrated by several signaling pathways. The best known involves VEGFC and its receptor VEGFR3. But another, less-publicized pathway is equally essential: the Angiopoietin/TIE pathway.
This pathway includes two receptors — TIE1 and TIE2 — and their angiopoietin ligands (ANGPT1, ANGPT2, ANGPT4). TIE2 is well characterized: it directly binds angiopoietins and activates pro-survival pathways like PI3K/AKT. TIE1 remains more mysterious: it doesn't directly bind angiopoietins but modulates TIE2 activity through the formation of TIE1/TIE2 heterodimers.
Three TIE1 variants identified in a cohort of 755 patients
Through whole-exome sequencing (WES), the team identified three rare TIE1 variants:
| Patient |
Mutation |
Type |
Affected domain |
| LE-580 |
Q682* (c.2044C>T) |
Premature stop codon |
Extracellular domain |
| LE-528 |
R983W (c.2947C>T) |
Missense |
Kinase domain |
| LE-21 |
M1110R (c.3329T>G) |
Missense |
Kinase domain |
The three variants are extremely rare in population databases (gnomAD, deCAF, RGC-MCPS). Both missense variants are predicted pathogenic by 19 out of 20 bioinformatic algorithms. All three patients have late-onset lymphedema (beginning in adulthood), primarily affecting the lower limbs.
Molecular mechanisms of the loss of function
Q682* variant: The premature stop codon generates an unstable mRNA degraded via the NMD (nonsense-mediated decay) pathway. In practice, the mutant allele is nearly undetectable in the patient's lymphoblasts. The potential truncated protein — a secreted form of the extracellular domain — would be inactive.
R983W and M1110R variants: These kinase-domain substitutions significantly reduce TIE1 signaling activity in vitro. Angiopoietin-induced TIE1 phosphorylation is decreased, compromising TIE2 modulation and downstream PI3K/AKT activation.
In vivo validation by CRISPR/Cas9 editing
The team reproduced both missense variants in mice via CRISPR/Cas9. Heterozygous mice develop visible edema. Homozygous mice die — confirming TIE1's essential role in vascular development. These in vivo functional results reinforce the pathogenicity of the identified human variants.
🔍 Key points
- →TIE1 loss of function → altered TIE2 modulation → lymphatic dysfunction
- →Complements the previous discovery: ANGPT2 LOF → primary lymphedema
- →Highlights the central role of the ANGPT2/TIE1 pathway in lymphatic function
✦ What it changes in practice
TIE1 should now be included in all genetic diagnostic panels for primary lymphedema.
That's the direct and immediate implication of this study. Today, testing TIE1 isn't yet standard — for lack of sufficient data. This publication changes the landscape. And therapeutically, the ANGPT2/TIE1 pathway is already a target being explored in other vascular contexts. These results could justify trials targeting this pathway in primary lymphedema — first in carriers of identified TIE1 mutations, then more broadly if results warrant.
✦ Extended abstract
Brouillard et al. report the identification of three heterozygous TIE1 loss-of-function variants in patients with late-onset primary lymphedema, drawn from a WES cohort of 755 individuals. In vitro functional studies and CRISPR/Cas9 mouse models establish the pathogenicity of these variants and underscore the critical role of ANGPT2/TIE1 signaling in lymphatic vascular homeostasis.
Background: the ANGPT/TIE pathway in lymphatic development
TIE1, a receptor tyrosine kinase with EGF-like and immunoglobulin-like extracellular domains, was initially described in 1992 as an orphan receptor. Its structural partner TIE2 directly binds angiopoietins (ANGPT1 agonist, ANGPT2 context-dependent) and activates PI3K/AKT, MAPK, and DOK-R pathways. TIE1 modulates this signaling through context-dependent TIE1/TIE2 heterodimerization: it potentiates ANGPT1 agonist activity and ANGPT2 autocrine activity via TIE2-dependent TIE1 phosphorylation.
Inflammation-induced TIE1 ectodomain cleavage modulates the ANGPT2 agonist/antagonist switch on TIE2. Additionally, AKT activation mediated by autocrine ANGPT2 and TIE1 conditions VEGFR3 expression on lymphatic endothelial cells — mechanistically linking the two major lymphangiogenesis pathways.
Methodology: WES, bioinformatic analysis, and functional models
Cohort: 755 index individuals with primary lymphedema, from whom 33 known causative genes had been previously excluded. TIE1 variants were filtered on rarity (absent or allele frequency <10⁻⁵ in gnomAD v3, deCAF, and RGC-MCPS) and in silico prediction (consensus of 20 algorithms).
Q682* variant characterization: RT-PCR on the patient's EBV-immortalized lymphoblasts: the mutant allele is nearly undetectable relative to the WT allele, confirming NMD degradation. The unaffected carrier son shows partial degradation (~50% of the mutant allele), suggesting penetrance linked to individual NMD efficiency and potentially to age.
Missense variant characterization: The kinase-domain substitutions R983W and M1110R reduce TIE1 phosphorylation induced by pentameric Comp-ANGPT1 in transfected endothelial cells (BAECs), with decreased downstream AKT activation. Structural analysis (modeled on the crystallized TIE2 kinase domain) predicts conformational disturbances affecting the activation loop (R983W) and the C-terminal lobe (M1110R).
Mouse models: The R983W and M1110R variants were reproduced in C57BL/6 mice via CRISPR/Cas9 (RNP zygote injection). Heterozygotes develop subcutaneous edema with variable penetrance. Homozygotes are perinatally lethal, phenocopying total Tie1 KO (death from defective late-gestation vascular maturation). Histological analyses confirm collecting-vessel lymphatic hypoplasia in heterozygotes.
Implications for primary lymphedema genetics
These results add TIE1 to the 33 confirmed causative genes of primary lymphedema, and reinforce the role of the ANGPT/TIE pathway — following the same group's demonstration that ANGPT2 LOF variants also cause autosomal dominant primary lymphedema. The ANGPT2 LOF + TIE1 LOF → primary lymphedema convergence mechanistically establishes the ANGPT2/TIE1 pathway as a non-redundant regulator of lymphatic function.
TIE1 variant frequency in the cohort (3/755, ~0.4%) is comparable to that of other incompletely penetrant primary lymphedema genes. The observed variable penetrance (the Q682* carrier son is unaffected at age 14) suggests genetic or environmental modifiers, and is consistent with the late-onset phenotype characteristic of this entity.
🔬 Limitations & outlook
- →Limited cohort size — 3 patients in 755 does not allow a robust estimate of true prevalence
- →Incomplete penetrance: the modifier mechanisms remain to be elucidated (NMD efficiency, ANGPT2 expression, age of onset)
- →Therapeutic potential: the ANGPT2/TIE1/TIE2 pathway is a target for TIE2 agonists (e.g. vascular endothelial growth factor inhibitors, COMP-ANGPT1 variants) — prospects for function-replacement therapy
- →TIE1 should be integrated into NGS diagnostic panels for primary lymphedema
✦ Critical reading
A rigorous study, but a cohort that calls for independent replication.
With 3 patients in 755, statistical power is necessarily limited and the true prevalence estimate of TIE1 variants in primary lymphedema remains uncertain. The observed incomplete penetrance — the Q682* carrier son is asymptomatic at age 14 — suggests that TIE1 alone does not always suffice to cause disease. Modifying factors, genetic or environmental, remain to be identified. None of this diminishes the publication's value: the functional data (NMD, kinase activity, CRISPR mice) are solid and the mechanism is biologically plausible. This is a first proof of principle, not an epidemiological study. And that's exactly what this field needed to move forward.
Primary source
Brouillard P, Murtomäki A, Leppänen VM, et al. Loss-of-function mutations of the TIE1 receptor tyrosine kinase cause late-onset primary lymphedema. J Clin Invest. 2024;134(14):e173586. doi:10.1172/JCI173586. Prof. Miikka Vikkula — UCLouvain, de Duve Institute, Brussels.
